In 1935, Cipla was founded by Dr.Khwaja Abdul Hamied as a small Indian enterprise that was committed to nation’s quest for self-sufficiency. During the Second World War Cipla proved itself by meeting the challenge of alarming shortage of essential medicines. Cipla pioneered the bulk drug manufacturing market by the 1960s.

Cipla has committed production plants for Oncology products, Hormones, Inhalers, Carbapenems, and cephlosporins, among other products. Its API manufacturing plants have the capability of complex multi-stage syntheses and can manufacture over 120 APIs from high potency actives in grams to those made in several tonnes.
Cipla has a wide range of products and dosages forms, everything from nasal sprays, metered-dose inhalers, medical devices, trans-dermal spray patches, thermolabile foams, pre-filled syringes, and lyophilized injections.

Cipla has 7000 employees, who are known for their continuous quest for quality. For them quality is obsession.

Cipla had opened the door of hope to several AIDS patients by becoming the first company in the world to offer the Triple-drug AIDS Cocktail at a very low price. According to an estimate, one out of three HIV-AIDS patients in Africa takes Cipla drug for the treatment.

In partnership with the medical fraternity, Cipla has spread awareness and empowered asthma patients to lead a normal life. It has the widest range of asthma medication and better delivery systems. Cipla is also dedicated to clinical and allied research in the field of Chronic Respiratory Diseases.

Recently, the company has entered into agreement with a global non-profit organization for developing and manufacturing Drugs for Neglected diseases Initiative (DNDi) for a new anti-malarial combination drug.

Corporate Address:
Cipla Ltd.
Mumbai Central
Mumbai 400 008
India.
Ph: 022-23082891
022-23095521
Fax: 91-22-2307-0013
91-22-2307-0393

Quarterly Reports of Cipla

Quarterly Results (Rs. in Millions)
Dec 2006 (3 rd quarter) Sept 2006(2nd quarter) Dec 2005 (3 rd quarter)
Sales Turnover 9045 9152.6 8119.2
Other Income 261.3 189.9 744.5
Total Income 9306.3 9342.5 8863.7
Total Expenditure 6852.3 6876.6 6529.9
Operating Profit 2454 2465.9 2333.8
Interest 13.2 15.6 50.7
Gross Profit 2440.8 2450.3 2283.1
Depreciation 275 245 230
Tax 322 402.5 300
Reported PAT 1843.8 1802.8 1753.1

*Source: economictimes.indiatimes.com

Quarterly Results (in %)
% Change (Over Sep 2006) % Change (Over Dec 2005)
Sales Turnover -1.18 11.4
Other Income 37.6 -64.9
Total Income -0.39 4.99
Total Expenditure -0.35 4.94
Operating Profit -0.48 5.15
Interest -15.38 -73.96
Gross Profit -0.39 6.91
Depreciation 12.24 19.57
Tax
Reported PAT 2.27 5.17

*Source: economictimes.indiatimes.com

Annual Results of Cipla

Annual Unaudited Results (Rs. in Millions)
(12 Months) (12 Months) % Changes
Sales Turnover 31142.00 24008.70 29.71
Other Income 1216.30 819.8 48.37
Total Income 32358.30 24828.50 30.33
Total Expenditure 24343.90 19055.60 27.75
Operating Profit 8014.40 5772.90 38.83
Interest 114.2 76.3 49.67
Gross Profit 7900.20 5696.60 38.68
Depreciation 801.8 550.5 45.65
Tax 1022.00 1050.00 -2.67
Reported PAT 6076.40 4096.10 48.35

*Source: economictimes.indiatimes.com